View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of August 2019.
The “Reject Due To” information contained in our online test catalog is being updated to provide greater clarity around rejection standards.
In August 2019, Mayo Clinic Laboratories announced four new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
PD-L1 immunohistochemistry (IHC) is indicated in patients with specific tumor types in order to predict their responses to treatment with PD-L1 inhibitors. The specific PD-L1 clone, scoring method, and eligibility requirements are dependent on the tumor type, stage of malignancy, previous treatment outcomes, and specific PD-L1 inhibitor being considered.
With input from Mayo Clinic oncologists, our laboratories have developed a menu of next-generation sequencing (NGS) oncology panels. These panels aid in the diagnosis and management of patients with cancer and are optimized for clinically relevant genes and actionable targets consistent with current oncology guidelines.
View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of July 2019.
In July 2019, Mayo Clinic Laboratories announced six new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Ann Moyer, M.D., Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.
View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of June 2019.
Antimicrobial susceptibility testing determines whether these bacteria are susceptible or resistant to a particular antibiotic. Bacteria are added onto plates of solid agar, where each plate has a different and increasing concentration of antibiotic than the previous plate. The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial that inhibits growth of the bacteria.
In June 2019, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
David Viswanatha, M.D., a hematopathologist and co-director of the molecular hematology and complete genome sequencing laboratories at Mayo Clinic, provides an overview of BCR/ABL1 testing, discusses the best testing methods, NCCN/ELN criteria guidelines, why FISH testing is no longer routinely available at Mayo Clinic, and what test to order at what time for CML patients.
Targeted cancer therapies are defined as antibody or small molecule drugs that block the growth and spread of cancer by interfering with specific cell molecules involved in tumor growth and progression. Multiple targeted therapies have been approved by the US Food and Drug Administration (FDA) for treatment of specific cancers. Molecular genetic profiling is often needed to identify targets amenable to targeted therapies and to minimize treatment costs and therapy-associated risks.